Mr. Abdollahian has over 13 years of management and research experience in the life sciences industry. His experience in biopharmaceutical management includes more than 30 transactions ranging from early-stage technology collaborations, clinical-stage licensing transactions to acquisition and divestment of marketed therapeutics and companies. Most recently, Mr. Abdollahian was Director of Business Development & Special Projects at Emerging Growth Capital Pty, a biotech focused Australian investment bank. Prior to EG Capital, he spent 8 years leading and closing high-value biotech transactions while at Avanir Pharmaceuticals, Isis Pharmaceuticals and Neurogen Corporation. Mr. Abdollahian began his career in the research sciences where his graduate research focused on neuronal energy metabolism. He earned an MBA from Pepperdine University, an M.S. in the Biomedical Sciences from the University of New Mexico School of Medicine and a B.S. in the Biological Sciences from the George Washington University.